Next Article in Journal
Detecting Early-Stage Oral Cancer from Clinically Diagnosed Oral Potentially Malignant Disorders by DNA Methylation Profile
Next Article in Special Issue
Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
Previous Article in Journal
A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells
 
 
Article
Peer-Review Record

The AKT1E17K Allele Promotes Breast Cancer in Mice

Cancers 2022, 14(11), 2645; https://doi.org/10.3390/cancers14112645
by Donatella Malanga 1,2,*, Carmelo Laudanna 3, Teresa Mirante 1, Fabiana Colelli 4, Simona Migliozzi 1, Pietro Zoppoli 1, Gianluca Santamaria 1, Luca Roberto 4, Carmela De Marco 1, Marzia Scarfò 5, Donatella Montanaro 6, Orlando Paciello 7, Serenella Papparella 7, Chiara Mignogna 2,8, Alfonso Baldi 6,9 and Giuseppe Viglietto 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2022, 14(11), 2645; https://doi.org/10.3390/cancers14112645
Submission received: 6 April 2022 / Revised: 23 May 2022 / Accepted: 24 May 2022 / Published: 26 May 2022
(This article belongs to the Collection Molecular Signaling Pathways and Networks on Cancer)

Round 1

Reviewer 1 Report

The authors have investigated the role of gain of function mutation E17K in AKT1 in driving mammary tumors using MMTV-CRE;R26-AKT1E17K mice models. They observed spontaneous mammary tumors in mice expressing AKT1E17 as compared to WT. Immunohistochemical characterization suggested basal like marker expression as they were PR-/HER2-/ER +, basal-like and CK8-/CK10-/CK5+ /CK14+. Further, GSEA of tumors expressing mutant AKT1E17K presented activation of the GSK3/cyclin D1 pathway in the mammary epithelium and clustering with the human basal-like tumors. They conclude that AKT1E17K is a bona fide oncogene that is initiates tumors at high efficiency in murine mammary epithelium.

Overall, it's an interesting research topic, exploring subtype formation from AKT mutant in breast cancer. Some concerns are as follows:

Figure 1C and 2A, please includes images with better resolution for both 20X and 40X magnification. ER expression is not clearly visible in the current figure.

Does the differences in dysplasia or proliferative index varied with or depend on parity of mice?

What percentage of tumors derived from AKTE17K were ER positive?
Can you include bar diagrams to depict IHC data in terms of percentage among low grade and high grade tumors. 

Given the heterogenity in differentiation in tumors from AKTE17K, does the low differentiated tumors (that were not included in the analysis) express the markers or gene signatures derived from Gene array analysis or other basal like markers?

For some reason the supplementary files were not properly opening. Please make sure the correct version/format of files were uploaded.

Minor:

Please review the manuscript for spelling and space errors to maintain uniformity.

In methods, mice euthanasia was performed by inhaling carbon monoxide. Please make sure you follow the recommended guidelines for euthanasia, as Carbon dioxide is the most commonly used method for this purpose. Please correct if that was wrongly written. 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The aim of the present study was to evaluate the role of AKT1E17K in the transformation of breast epithelial cells in vivo. Two suggestions is as following:

In the Introduction, the authors mention that "Mutant AKT1E17K protein shows increased affinity for PI(4,5)P2, which allows its recruitment to plasma membrane and constitutive activation (15, 18)." It is better to evaluate PI(4,5)P2 binding affinity in the animal model.

Materials and methods: some more sentences to explain "mouse mammary tumor virus (MMTV)" is necessary (better).

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop